http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2023
-
Genmab A/S (GMAB) and argenx (ARGX) Partner to Advance Antibody Therapies in Immunology and Oncology
-
argenx and Genmab Enter Partnership to Advance Antibody Therapies in Immunology and Oncology
-
Genmab and argenx Enter Partnership to Advance Antibody Therapies in Immunology and Oncology
-
Genmab and argenx Enter Partnership to Advance Antibody Therapies in Immunology and Oncology
-
Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
-
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
-
Completion of share buy-back program
-
Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
-
Genmab A/S (GMAB) Appoints Martine van Vugt as Chief Strategy Officer
-
Genmab Announces Appointment of Martine van Vugt to Chief Strategy Officer
-
Transactions in connection with share buy-back program
-
Transactions in connection with share buy-back program
-
Transactions in connection with share buy-back program
-
Transactions in connection with share buy-back program
-
Capital Increase in Genmab as a Result of Employee Warrant Exercise
-
Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
-
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
-
Genmab Files Annual Report with the U.S. Securities and Exchange Commission
-
Genmab (GMAB) Announces Initiation of Share Buy-Back Program
-
Genmab Announces Initiation of Share Buy-Back Program
-
Genmab Publishes 2022 Annual Report
-
Genmab A/S (GMAB) Reports 2022 Net Sales of DARZALEX of $7.98B
-
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2022
-
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2022
-
Correction to Company Announcement No. 1 of January 3, 2023
-
Genmab Announces Submission of Japan New Drug Application (JNDA) for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
-
Genmab Announces Submission of Japan New Drug Application (JNDA) for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
-
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
-
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
-
Genmab Showcases Data From Robust Development Program Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients Across a Broad Range of B-Cell Lymphomas at the 64th Annual ASH Meeting
-
Genmab Showcases Data From Robust Development Program Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients Across a Broad Range of B-Cell Lymphomas at the 64th Annual ASH Meeting
-
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
-
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
-
Genma (GMAB) Announces FDA Accepts for Priority Review BLA for Epcoritamab for the Treatment of Relapsed/Refractory LBCL
-
Genmab Announces U.S. Food and Drug Administration Accepts for Priority Review Biologics License Application (BLA) for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B
-
Genmab Announces U.S. Food and Drug Administration Accepts for Priority Review Biologics License Application (BLA) for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B
-
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
-
Genmab Improves Its 2022 Financial Guidance
-
Genmab Announces Multiple Abstracts to be Presented at the 64th Annual Meeting and Exposition of the American Society of Hematology (ASH)
-
Genmab Announces Multiple Abstracts to be Presented at the 64th Annual Meeting and Exposition of the American Society of Hematology (ASH)
-
Genmab A/S (GMAB) Announces Submissions of Regulatory Applications for Epcoritamab for Relapsed/Refractory LBCL and DLBCL
-
Genmab Announces Submissions of Regulatory Applications for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL) and Diffuse Large B-Cell Lymphoma (DL
-
Genmab Announces Submissions of Regulatory Applications for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL) and Diffuse Large B-Cell Lymphoma (DL
-
Genmab A/S (GMAB) Reports Q4 DARZALEX Sales of $2.05M
-
Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2022
-
Major Shareholder Announcement
-
Zai Lab Limited (ZLAB) and Seagen (SGEN) Enter Collaboration and License Agreement for TIVDAK
-
Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for TIVDAK® (tisotumab vedotin-tftv)
-
Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for TIVDAK® (tisotumab vedotin-tftv)
